Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475917 · ClinicalTrials.gov registry record · Phase 1
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00475917: Clinical Trial Phase 1 study, sponsored by Exelixis.
NCT00475917 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475917, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
Interventions
- DRUG Gemcitabine
- DRUG XL844
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Why NCT00475917 stopped before completion
NCT00475917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00475917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00475917 about?
NCT00475917 is a clinical study titled "A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies". The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.
What is the current status of trial NCT00475917?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00475917?
The interventions under investigation include: Gemcitabine (DRUG), XL844 (DRUG).
Who is sponsoring clinical trial NCT00475917?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00475917's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia